Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Hepatology

• Publication date

  2001-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0168-8278(01)00062-9PMID 11434622
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Natural history of hepatitis C: Its impact on clinical management

  2000cited by this paper
• Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy

  2000cited by this paper
• The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States

  2000cited by this paper
• Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials

  1999cited by this paper
• Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma.

  1999cited by this paper
• Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

  1999cited by this paper
• The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

  1999cited by this paper
• Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long‐term sustained response to interferon‐alpha therapy

  1998cited by this paper
• Relation of Interferon Therapy and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C

  1998cited by this paper
• Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection

  1998cited by this paper
• Combination therapy for hepatitis C infection.

  1998cited by this paper
• Determinants of outcome of compensated hepatitis C virus‐related cirrhosis

  1998cited by this paper
• Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C

  1998cited by this paper
• Interferon alfa for chronic hepatitis C: how do we define cure?

  1998cited by this paper
• Long-term course of interferon-treated chronic hepatitis C.

  1998cited by this paper
• Combination Therapy for Hepatitis C Infection

  1998cited by this paper
• Interferon-alpha in chronic hepatitis C.

  1998cited by this paper
• 10‐year follow‐up after interferon‐α therapy for chronic hepatitis C

  1998cited by this paper
• Can HCV infection be cleared?

  1998cited by this paper
• 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

  1998cited by this paper
• Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon- Therapy

  1997cited by this paper
• The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis.

  1997cited by this paper
• Interferon-alpha for chronic hepatitis C: reducing the uncertainties.

  1997cited by this paper
• Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: A meta‐analysis of diagnostic test characteristics

  1997cited by this paper
• Interferon- in Chronic Hepatitis C

  1997cited by this paper
• Interferon- for Chronic Hepatitis C: Reducing the Uncertainties

  1997cited by this paper
• Persistent Hepatitis C Viremia Predicts Late Relapse after Sustained Response to Interferon- in Chronic Hepatitis C

  1996cited by this paper
• Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group.

  1996cited by this paper
• Two‐year biochemical, virological, and histological follow‐up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa‐2b treatment

  1995cited by this paper
• Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

  1995cited by this paper
• Interferon‐α for chronic hepatitis C: An analysis of pretreatment clinical predictors of response

  1994cited by this paper
• Quantitation of hepatitis C virus genome molecules in plasma samples

  1994cited by this paper
• Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response.

  1994cited by this paper
• A proposed system for the nomenclature of hepatitis C viral genotypes

  1994cited by this paper
• Virological features of hepatitis C virus infection in hemodialysis patients

  1993cited by this paper
• Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources.

  1992cited by this paper
• Factors predicting early response to treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis. Preliminary report of a long-term trial.

  1992cited by this paper
• Analysis of serial measurements in medical research.

  1990cited by this paper
• An assessment of clinically useful measures of the consequences of treatment.

  1988cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper
• Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

  1981cited by this paper

• 2023 Semmelweis Lecture: Sepsis Is a Myth*

  2025cites this paper
• Histological improvement of fibrosis in patients with hepatitis C who achieved a 5-year sustained virological response to treatment with direct-acting antivirals

  2024cites this paper
• Assessment of Factors Affecting Response of Direct-Acting Antivirals in Chronic Hepatitis C Patients

  2023cites this paper
• Sofosbuvir induces gene expression for promoting cell proliferation and migration of hepatocellular carcinoma cells

  2022cites this paper
• Treatment of hepatitis C virus infection and associated glomerular disease

  2020cites this paper
• In vivo induction of hepatocellular carcinoma by diethylnitrosoamine and pharmacological intervention in Balb C mice using Bergenia ciliata extracts.

  2019cites this paper
• Función del inflamasoma AIM2 en el desarrollo de carcinoma hepatocelular

  2019cites this paper
• Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C

  2018cites this paper
• Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting

  2018cites this paper
• Efficacy and Safety of Sofosbuvir-Based Direct Acting Antivirals for Hepatitis C in Septuagenarians and Octogenarians.

  2017cites this paper
• Direct-acting antivirals (daas) increase the serum vegf level in patients with chronic hepatitis c: a rationale for tumor recurrence

  2017cites this paper
• Modifications of hepatic fibrosis assessed by transient elastometry in patients with sustained virological response after treatment of hepatitis C in monoinfected (VHC) and coinfected patients(VHC – VIH)

  2017cites this paper
• Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North India.

  2017cites this paper
• ustained virological response to pegylated interferon plus ribavirin leads to ormalization of liver stiffness in hepatitis C virus-infected patients

  2017cites this paper
• Utilidad de la elastografía de transición tras la respuesta virológica en la hepatitis crónica por el virus de la hepatitis C Usefulness of liver stiffness measurement after antiviral response in chronic hepatitis C

  2016cites this paper
• Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C

  2016cites this paper
• Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin

  2016cites this paper
• Evolving therapies for hepatitis C virus in chronic kidney disease: the beginning of a new era

  2016cites this paper
• Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders

  2016cites this paper
• Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy.

  2015cites this paper
• Is widespread screening for hepatitis C justified?

  2015cites this paper
• Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection.

  2015cites this paper
• Chapter 11 – Transplantation for Hepatitis C

  2015cites this paper
• Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta‐analysis

  2015cites this paper
• Hepatitis C Infection in the Elderly

  2015cites this paper
• Chronic Hepatitis C in the Aged: Much Ado About Nothing or Nothing to Do?

  2014cites this paper
• Cirrhosis Regression in Patients With Viral Hepatitis B and C: A Systematic Review

  2014cites this paper
• Durability of Sustained Virological Response and Long Term Follow Up To Pegylated Interferon and Ribavirin in Treated Patients with Chronic Hepatitis C

  2014cites this paper
• Etiological and molecular profile of hepatocellular cancer from India

  2013cites this paper
• Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma

  2013cites this paper
• [Usefulness of liver stiffness measurement after antiviral response in chronic hepatitis C].

  2013cites this paper
• [The burden of viral hepatitis in the Russian Federation requires reducing its progression for the long term, including chronic hepatitis C)].

  2013cites this paper
• Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.

  2013cites this paper
• Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis.

  2013cites this paper
• Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C.

  2012cites this paper
• Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long‐term follow‐up

  2012cites this paper
• New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye

  2012cites this paper
• Epidemiology of Chronic HCV

  2012cites this paper
• Long-term effects of peg-interferon alfa-2a and ribavirin in hemophilic patients with chronic hepatitis C

  2012cites this paper
• Viral Hepatitis Infections in Chronic Kidney Disease Patients and Renal Transplant Recipients

  2012cites this paper
• The Effect of Interferon and Ribavirin on Oxidative Stress in Chronic Hepatitis C Patients

  2012cites this paper
• Long-term viral negativity after interferon for chronic hepatitis C virus infection in hemodialysis.

  2011cites this paper
• Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.

  2011influential citation
• Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin.

  2011cites this paper
• Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C.

  2011cites this paper
• Criteria Grid Hepatitis C Research Studies , Tools , and Surveillance Systems

  2011cites this paper
• EVALUATION OF CLINICAL AND LABORATORY PARAMETERS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA Dissertation submitted in partial fulfillment of the requirements for the degree of D.M. (MEDICAL GASTROENTEROLOGY) Branch – IV THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY CHENNAI

  2010cites this paper
• The Healthcare Burden Imposed by Liver Disease in Aging Baby Boomers

  2010cites this paper
• Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon.

  2010cites this paper
• Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin.

  2010cites this paper
• Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection.

  2010cites this paper
• Risk Factors for Hepatocellular Carcinoma: A Case-Control Study in Belgrade (Serbia)

  2010cites this paper
• Hepatocellular Carcinoma – Epidemiological Trends and Risk Factors

  2009cites this paper
• GIORNALE EUROPEO DI ONCOLOGIA

  2009cites this paper
• REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY

  2009cites this paper
• Occult hepatitis C: How convincing are the current data?

  2009cites this paper
• KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD.

  2008cites this paper
• Long-term Clinical Outcome of Treatment for Chronic Hepatitis C

  2008cites this paper
• Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms.

  2008cites this paper
• Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow‐up and screening

  2008cites this paper
• HCV virological response during treatment of chronic hepatitis C is associated with liver histological improvement in patients with HCV/HIV co-infection.

  2008cites this paper
• In vivo confocal laser endomicroscopy of the human liver: a novel method for assessing liver microarchitecture in real time

  2008cites this paper
• Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

  2007cites this paper
• Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis

  2007cites this paper
• Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis.

  2007cites this paper
• Liver angiogenesis as a risk factor for hepatocellular carcinoma development in hepatitis C virus cirrhotic patients.

  2007cites this paper
• Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

  2007cites this paper
• Long-Term Effects of Interferon-Based Therapy for Chronic Hepatitis C

  2007influential citation
• Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon‐α therapy

  2006cites this paper
• Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment.

  2006influential citation
• Análise histológica comparativa de biópsias hepáticas de pacientes com hepatite C crônica, co-infectados pelo HIV-1, realizadas antes e após o tratamento da hepatite C

  2006cites this paper
• Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha.

  2006cites this paper
• Reasons for non‐treatment of hepatitis C in veterans in care

  2005cites this paper
• Histological outcome of chronic hepatitis B in children treated with interferon alpha.

  2005cites this paper
• The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach.

  2004cites this paper
• Pathogenesis of hepatitis C-associated hepatocellular carcinoma.

  2004cites this paper
• Immunological response in chronic hepatitis C virus infection during interferon alpha therapy.

  2004cites this paper
• Long‐term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy

  2004cites this paper
• Effect of peginterferon alfa‐2a on liver histology in chronic hepatitis C: A meta‐analysis of individual patient data

  2004cites this paper
• Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy

  2004cites this paper
• The impact of antiviral therapy on the course of chronic HCV infection. A systematic review.

  2003cites this paper
• Changes in Antipyrine Clearance and Platelet Count, but Not Conventional Liver Tests, Correlate With Fibrotic Change in Chronic Hepatitis C: Value for Predicting Fibrotic Progression

  2003cites this paper
• Long‐term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon

  2003cites this paper
• Viral hepatitis B.

  2003cites this paper
• Viral hepatitis C.

  2003cites this paper
• Oxidative stress in chronic hepatitis C: the effect of interferon therapy and correlation with pathological features.

  2003cites this paper
• [Evaluation of response to treatment in chronic hepatitis C].

  2002cites this paper
• The Clinician's Companion VI: Expert Perspectives on Contemporary Clinical Issues in Hepatitis C

  2002cites this paper
• Hepatocellular carcinoma and hepatitis C in the United States

  2002cites this paper
• Hepatocellular carcinoma and hepatitis C in the United States

  2002cites this paper
• Epidemiology of hepatocellular carcinoma.

  2001cites this paper
• Clinical Interventions in Aging Dovepress

  year unknowncites this paper